[at Seeking Alpha] – Gilead Sciences ( GILD ), a biopharmaceutical research company, indeed has traits of a growth stock. Gilead Sciences reported $9.7 billion in sales for the 2012 fiscal year. In the last three fiscal years, …
Read more on … [visit site to read more]
- AbbVie Inc. (NYSE:ABBV) ~ AbbVie’s hepatitis C treatment helps 96 pct of patients in trial
- The Procter & Gamble Company (NYSE:PG) – Companies’ most neglected resource for success
- Stock Update: Johnson & Johnson (NYSE:JNJ) – J&J’s new hepatitis C drug gets positive FDA review
